Dorman Products Inc (DORM)
Official siteCONSUMER CYCLICAL • AUTO PARTS • NASDAQ
Market Cap: $3.90B
Last updated: Nov 17, 2026 at 11:03 AM ET
Dorman Products Inc (DORM) Stock Forecast
Analysts expect Dorman Products (DORM) to earn $8.63 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.19B. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 25.0% |
| Buy | 6 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 5.6% and revenue estimates rise 4.6%.
- Fiscal year ending Dec 31, 2026
- $8.63
- EPS consensus, revenue $2.19B
- Fiscal year ending Dec 31, 2027
- $9.11
- EPS consensus, revenue $2.29B
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $8.63 | $8.50 to $8.67 | 8 | $2.19B | $2.18B to $2.19B | 8 |
| Dec 31, 2027 | $9.11 | $8.84 to $9.29 | 8 | $2.29B | $2.27B to $2.32B | 8 |
Quarterly Estimates
The EPS consensus rises from $1.97 for the quarter ending Dec 31, 2026 to $2.02 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.97 | $1.73 to $2.32 | 11 | $569.00M | $536.94M to $604.59M | 10 |
| Mar 31, 2027 | $2.02 | $1.64 to $2.30 | 7 | $546.04M | $534.06M to $561.90M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 11 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 4 |
| Fiscal year ending Dec 31, 2027 | 2 | 4 |
| Quarter ending Mar 31, 2027 | 1 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.2% from $8.28.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $8.63 | $8.66 | $8.66 | $8.67 | $8.28 | +4.2% |
| Fiscal year ending Dec 31, 2027 | $9.11 | $9.20 | $9.20 | $9.29 | $9.39 | -2.9% |
| Quarter ending Mar 31, 2027 | $2.02 | $2.00 | $2.00 | $2.04 | $1.98 | +2.1% |
Frequently Asked Questions About DORM
What is the DORM stock forecast?
Consensus analyst estimates put Dorman Products's EPS at $8.63 for the fiscal year ending Dec 31, 2026, on revenue of $2.19B. The consensus rating from 8 analysts is Buy.
How do analysts rate DORM stock?
Of 8 analysts covering Dorman Products, 2 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DORM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $8.63, with estimates from $8.50 to $8.67 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $9.11, with estimates from $8.84 to $9.29 from 8 analysts.
What revenue do analysts expect from Dorman Products next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.19B, with estimates from $2.18B to $2.19B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.29B, with estimates from $2.27B to $2.32B.
How many analysts cover DORM?
8 analysts rate Dorman Products stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DORM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors